#PrecisionOncology is an active hashtag on Bluesky. In the last 30 days, 19 people shared 45 posts with it — around 2 a day. Activity is up 140% versus the previous week, peaking on Jul 17 with 6 posts.
Tags most often used together with #PrecisionOncology.
www.science.org
RNA polymerase II at histone genes predicts outcome in human cancer
Genome-wide hypertranscription is common in human cancer and predicts poor prognosis. To understand how hypertranscription might drive cancer, we applied our formalin-fixed paraffin-embedded (FFPE)–cl...
www.xiahepublishing.com
Multimodal Fusion Artificial Intelligence Models for Pathological Diagnosis in Early Cervical Cancer Screening: A Narrative Review
Cervical cancer is a major malignancy that threatens women’s health, and early screening is a core strategy for reducing its incidence and mortality. Multimodal fusion artificial intelligence (AI) pathological diagnosis models integrate multidimensional data—including cytological images, colposcopic images, whole-slide histopathological images, clinical data, and molecular testing results—and may enhance the detection sensitivity, grading accuracy, and screening efficiency for early cervical cancer and precancerous lesions. However, traditional cervical cancer screening methods face limitations such as high subjectivity, reliance on single-source information, relatively low efficiency, and insufficient primary care resources. Furthermore, existing reviews mostly focus on single-modal AI models or specific technical aspects, lacking a comprehensive analysis of the full technical framework and clinical translation pathways of multimodal fusion models. This review aims to comprehensively present the development and application of multimodal fusion AI models in pathological diagnosis for early cervical cancer screening. Specifically, it comprehensively details the technical architecture, data modalities, and fusion strategies—including deep learning, attention mechanisms, and cross-modal alignment techniques—that enable the complementary representation of morphological, clinical, and molecular information. Additionally, the review integrates recent advances in clinical applications and evaluates current translational challenges, providing insights into clinical validation pathways to bridge technological innovation and practical healthcare delivery. In conclusion, with further technological refinement and clinical validation, multimodal fusion AI may become a useful tool for improving the precision and efficiency of cervical cancer screening and prevention, and may inform the standardized application and translational research of AI technology in this field.
www.onclive.com
Low Tumor PD-L1 Expression Identifies Responders to Neoadjuvant Leukocyte Interleukin Injection in Locally Advanced HNSCC | OncLive
Low PD-L1 expression and node-negative status identified oral cancer patients most likely to benefit from neoadjuvant leukocyte interleukin injection.
oncodaily.com
Encorafenib, cetuximab, and chemotherapy in BRAF-mutant colorectal cancer - OncoDaily
Encorafenib, cetuximab, and chemotherapy in BRAF-mutant colorectal cancer / Arndt Vogel, BRAF mutant CRC, BRAF mutation, BREAKWATER trial, cancer, Cancer
bit.ly
ASH 2024
Fred Hutch scientists will present the latest findings on transplantation, cell therapies, precision medicine and more at the 66th Annual American Society of Hematology meeting. The ASH meeting featur...
oncodaily.com
Thor Halfdanarson: CUP is increasingly precision oncology - OncoDaily
Thor Halfdanarson: CUP is increasingly precision oncology / cancer, carcinoma, CUP oncology, OncoDaily, Oncology, Precision Oncology, Thor Halfdanarson
www.onclive.com
Dostarlimab Monotherapy Elicits Responses in First-Line PD-L1-Positive HNSCC | OncLive
Dostarlimab monotherapy produced a 27% response rate in PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma
www.onclive.com
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer | OncLive
BI-1808 combined with pembrolizumab elicited a 24% confirmed overall response rate in heavily pretreated, platinum-resistant recurrent ovarian cancer.
www.xiahepublishing.com
Multimodal Fusion Artificial Intelligence Models for Pathological Diagnosis in Early Cervical Cancer Screening: A Narrative Review
Cervical cancer is a major malignancy that threatens women’s health, and early screening is a core strategy for reducing its incidence and mortality. Multimodal fusion artificial intelligence (AI) pathological diagnosis models integrate multidimensional data—including cytological images, colposcopic images, whole-slide histopathological images, clinical data, and molecular testing results—and may enhance the detection sensitivity, grading accuracy, and screening efficiency for early cervical cancer and precancerous lesions. However, traditional cervical cancer screening methods face limitations such as high subjectivity, reliance on single-source information, relatively low efficiency, and insufficient primary care resources. Furthermore, existing reviews mostly focus on single-modal AI models or specific technical aspects, lacking a comprehensive analysis of the full technical framework and clinical translation pathways of multimodal fusion models. This review aims to comprehensively present the development and application of multimodal fusion AI models in pathological diagnosis for early cervical cancer screening. Specifically, it comprehensively details the technical architecture, data modalities, and fusion strategies—including deep learning, attention mechanisms, and cross-modal alignment techniques—that enable the complementary representation of morphological, clinical, and molecular information. Additionally, the review integrates recent advances in clinical applications and evaluates current translational challenges, providing insights into clinical validation pathways to bridge technological innovation and practical healthcare delivery. In conclusion, with further technological refinement and clinical validation, multimodal fusion AI may become a useful tool for improving the precision and efficiency of cervical cancer screening and prevention, and may inform the standardized application and translational research of AI technology in this field.
www.onclive.com
Triplet Immunotherapy Regimen Yields Durable Responses in pMMR CRPC | OncLive
Adding an IL-15 receptor superagonist to a vaccine plus bintrafusp alfa produced clinical responses in pMMR CRPC.
www.onclive.com
Low Tumor PD-L1 Expression Identifies Responders to Neoadjuvant Leukocyte Interleukin Injection in Locally Advanced HNSCC | OncLive
Low PD-L1 expression and node-negative status identified oral cancer patients most likely to benefit from neoadjuvant leukocyte interleukin injection.
www.onclive.com
Signatera Is Submitted to Japan's PMDA for Companion Diagnostic Approval in MIBC | OncLive
Natera has submitted Signatera to Japan's PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer.
Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.